Adult Dosing

Acne vulgaris

• >12 yrs: Apply bid

Pediatric Dosing

• Safety and effectiveness in pediatric patients below the age of 12 have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Acne vulgaris

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Mild to life-threatening pseudomembranous colitis has been reported with erythromycin use. Consider this diagnosis in patients who present with diarrhea subsequent to the administration of erythromycin
• Erythromycin may alter the normal flora of the colon and may permit overgrowth of clostridia resulting in colitis
• Suspend therapy immediately after the diagnosis of pseudomembranous colitis
• Appropriately manage C. difficile colitis with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug
• For topical use only; not for ophthalmic use
• Concomitant acne therapy with the use of peeling, desquamating, or abrasive agents should be used with caution because a possible cumulative irritancy effect may occur
• Discontinue use and take appropriate measures if overgrowth of nonsusceptible organisms including fungi occurs
• Avoid contact with eyes and all mucous membranes

Pregnancy Category:C

Breastfeeding: Safety unknown; topical administration of erythromycin is acceptable in nursing mothers because of the low levels in breastmilk and safe administration directly to infants. The small amounts in milk are unlikely to cause adverse effects in the infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 15 December 2010). According to the manufacturer data it is not known whether this topical gel is secreted into human milk after topical application. Erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Caution advised while administering to a nursing woman.

• DERM: Dryness, urticarial reaction, irritation, peeling, itching, burning sensation, erythema, face inflammation, discoloration of skin, oiliness, tenderness
• EENT: Eye inflammation, nose inflammation
• GI: Pseudomembranous colitis

Benzoyl peroxide

• Antibiotic agent; major mechanism of action thought to be its antibacterial activity
• <2% absorbed after topical application
• Primarily metabolized in skin; CYP 450: Unknown
• Half-life: Unknown

Erythromycin

• Anti-infective (Macrolide); interferes with microbial protein synthesis by binding to P site of 50S ribosomal subunit
• Minimal absorption on topical application
• Metabolized by liver >90%; CYP450: 3A4 substrate/inhibitor
• Excreted mainly in bile, urine (5% unchanged)
• Half-life: Unknown

US Trade Name(s)

• Benzamycin

US Availability

Benzamycin (benzoyl peroxide/erythromycin)

• GEL: 5%/3% (23.3 gm plastic vial)

Canadian Trade Name(s)

• Benzamycin

Canadian Availability

Benzamycin (benzoyl peroxide/erythromycin)

• GEL: 5%/3% (23.3 gm plastic vial)

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Anti-Acne Agents

Pricing data from www.DrugStore.com in U.S.A.

• Benzamycin 5-3 % GEL [Jar] (DERMIK)
  46.6 % = $230
  139.8 % = $665.95
• BenzamycinPak 5-3 % PACK [Packet] (DERMIK)
  60 % = $152.99
  180 % = $445.96

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.